Shares of Viking Therapeutics VKTX rose about 9% on Wednesday after the company expanded its obesity pipeline by advancing a ...

In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; ...

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today the ...

Viking Therapeutics starts Phase 1 study on novel weight loss drug in healthy adults: San Diego Thursday, June 25, 2026, 18:00 Hrs [IST] Viking Therapeutics, Inc., a clinical-stag ...

To demonstrate effect of completion time of initiation phase of anti-vascular endothelial growth factor (anti-VEGF) agents on visual and anatomical outcomes in diabetic macular oedema patients. The ...

Phase 2 study designed to evaluate the pharmacodynamic effects, pharmacokinetics, and tolerability of ALTO-203 in patients with major depressive disorder (MDD) and higher levels of anhedonia ALTO-203 ...

The Phase 1 clinical trial currently recruiting is a pharmacokinetic bridging study in the U.S. designed as a single-dose, single-center, open-label, randomized 2-way crossover study of TH104 and an ...

Shares of Dyne Therapeutics DYN rose 10% on Wednesday after the company announced the initiation of the phase III FORZETTO study evaluating the safety and efficacy of zeleciment rostudirsen ...

– SER-301 is designed to target the physiological triggers of inflammation believed to be central to the underlying pathology of ulcerative colitis – – Program represents Seres’ second active clinical ...

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss ...